...
Loading...4 min read

The Promise of Immuno-oncology in Bladder Cancer

Bladder cancer treatments are hampered by high recurrence, requiring multiple therapeutic interventions which are highly invasive and cause side effects, underscoring the need for innovative treatments. In the pursuit of advancing bladder cancer treatment, immuno-oncology shows promise. This blog delves into the importance of identifying antigens in the development of targeted cancer therapies.  

Elizabeth Bolitho

October 2, 2023

Loading...4 min read

Targeting Autophagy for Obesity Treatment

Obesity is closely connected to autophagy, a vital cellular process impacting metabolic health. Targets which affect autophagy may therefore be a promising therapeutic approach.

Elizabeth Bolitho

September 28, 2023

Loading...4 min read

Identifying Targets for Alzheimer’s Disease: MAPK14

Despite progress, there is no cure for AD, necessitating on-going research into biological targets to develop effective treatments. Using Causaly, MAPK14 was identified as a potential target associated with AD progression which has been studied in mice.    

Elizabeth Bolitho

September 20, 2023

Filter by:

Oncology

Elizabeth Bolitho • October 2, 2023

The Promise of Immuno-oncology in Bladder Cancer

Bladder cancer treatments are hampered by high recurrence, requiring multiple therapeutic interventions which are highly invasive and cause side effects, underscoring the need for innovative treatments. In the pursuit of advancing bladder cancer treatment, immuno-oncology shows promise. This blog delves into the importance of identifying antigens in the development of targeted cancer therapies.  

Elizabeth Bolitho • September 4, 2023

Targeting GOF Mutations in Leukemia: FLT3 and NOTCH1

Understanding GOF mutations is crucial for developing targeted therapies which inhibit the activity of aberrant proteins. Here, we explored FLT3 and NOTCH1 as GOF mutations associated with leukemia disease progression.

Elizabeth Bolitho • August 1, 2023

MicroRNAs as Targets for Lung Cancer

miRNA therapeutics face numerous challenges including targeted delivery, specificity, stability, immune response, and toxicity. Overcoming these challenges is paramount for success.

Elizabeth Bolitho • July 27, 2023

Identifying Targets for Oral Cancer

Head and neck cancers account for nearly 4% of all cancers in the US. The most common type is oral cancer, estimated to cause over 170,000 global deaths in 2020 alone. These statistics highlight the urgent need for more research and better treatments.

Elizabeth Bolitho • July 12, 2023

Identifying Targets in Gastrointestinal Stromal Tumors

Gastrointestinal (GI) stromal tumors are a rare form of soft tissue sarcoma of the digestive system, primarily affecting the stomach and small intestine. In the US, approximately 6000 new cases of GI stromal tumors are diagnosed each year. Despite their rarity, these tumors are the most prevalent mesenchymal tumors of the GI tract.

Elizabeth Bolitho • June 15, 2023

Target Identification and Prioritization: A Kidney Cancer Use Case

Dive into groundbreaking research on Renal Cell Cancer, the most common kidney cancer in adults. Our blog explores innovative strategies for target identification, prioritization, and how these contribute to preventing and tackling this disease.